Table 3.
Distribution of clinicopathological variables within groups of patients as revealed by hierarchical clustering
| Clusters of patientsa | ||||||
| A | B | C | ||||
| I | II | III | IV | V | ||
| Distribution | Count | 27 | 23 | 24 | 22 | 9 |
| Age | Mean | 64.3 | 58.3 | 59.6 | 55.7 | 55.4 |
| p5 = 0.235, p3 = 0.212, N = 105 | Median | 64 | 55 | 60 | 57 | 49 |
| Tumor type | Lobular and mixed ductal/lobular | 12 | 5 | 5 | 4 | 1 |
| p5 = 0.040*, p3 = 0.021*, N = 105 | Ductal not otherwise specified | 15 | 17 | 16 | 14 | 4 |
| Mucinous, papillary | 0 | 0 | 2 | 2 | 1 | |
| Medullary, spindle cell | 0 | 1 | 1 | 2 | 3 | |
| Lymph node metastases | Absent | 10 | 8 | 6 | 12 | 5 |
| p5 = 0.240, p3 = 0.065, N = 105 | Present | 17 | 15 | 18 | 10 | 4 |
| Maximal tumor diameter | <20 mm (pT1) | 6 | 11 | 12 | 13 | 0 |
| p5 = 0.001*, p3 = 0.408, N = 105 | > 20 mm (pT2, pT3) | 21 | 12 | 12 | 9 | 9 |
| Tumor grade | Grade 1 | 8 | 5 | 7 | 7 | 2 |
| p5 = 0.138, p3 = 0.199, N = 105 | Grade 2 | 14 | 7 | 10 | 5 | 1 |
| Grade 3 | 5 | 11 | 7 | 10 | 6 | |
| Nuclear grade | Grade 1 | 6 | 2 | 2 | 6 | 2 |
| p5 < 0.001**, p3 < 0.001**, N = 105 | Grade 2 | 17 | 15 | 20 | 9 | 0 |
| Grade 3 | 4 | 6 | 2 | 7 | 7 | |
| Estrogen receptor alpha | Positive | 25 | 18 | 24 | 15 | 3 |
| p5 < 0.001**, p3 < 0.001**, N = 105 | Negative | 2 | 5 | 0 | 7 | 6 |
| Estrogen receptor beta | Positive | 20 | 11 | 13 | 8 | 3 |
| p5 = 0.078, p3 = 0.030*, N = 99 | Negative | 7 | 8 | 10 | 13 | 6 |
| Progesterone receptor | Positive | 23 | 16 | 24 | 14 | 4 |
| p5 < 0.001**, p3 < 0.001**, N = 105 | Negative | 4 | 7 | 0 | 8 | 5 |
| HER2 amplification by fluorescence in situ hybridization | Absent | 25 | 16 | 22 | 19 | 9 |
| p5 = 0.071, p3 = 0.398, N = 105 | Present | 2 | 7 | 2 | 3 | 0 |
| HER2/neu by immunohistochemistry | 3+ | 2 | 5 | 2 | 3 | 0 |
| p5 = 0.008*, p3 = 0. 046*, N = 105 | 2+ | 0 | 3 | 3 | 2 | 0 |
| 1+ | 10 | 10 | 7 | 2 | 1 | |
| 0 | 15 | 5 | 12 | 15 | 8 | |
| Cytokeratin 5/6 or cytokeratin 14 | Positive | 2 | 3 | 0 | 4 | 3 |
| p5 = 0.035*, p3 = 0.010*, N = 99 | Negative | 24 | 18 | 23 | 16 | 6 |
| Triple-negative phenotype | Yes | 0 | 1 | 0 | 5 | 6 |
| p5 < 0.001**, p3 < 0.001**, N = 105 | No | 27 | 22 | 24 | 17 | 3 |
| Cyclin D1 amplification by fluorescence in situ hybridization | Absent | 22 | 21 | 18 | 17 | 9 |
| p5 = 0.354, p3 = 0.875, N = 102 | Present | 5 | 2 | 4 | 4 | 0 |
| Cyclin D1 by immunohistochemistry | Positive | 26 | 17 | 21 | 18 | 4 |
| p5 = 0.001**, p3 = 0.111, N = 101 | Negative | 0 | 5 | 2 | 3 | 5 |
| Mucin 1 | 2+ | 17 | 12 | 21 | 9 | 1 |
| p5 = 0.001**, p3 < 0.001**, N = 102 | 1+ | 9 | 10 | 2 | 7 | 7 |
| 0 | 1 | 0 | 0 | 5 | 1 | |
| Gross cystic fluid protein | Positive | 10 | 10 | 13 | 9 | 2 |
| p5 = 0.572, p3 = 0.440, N = 98 | Negative | 15 | 13 | 10 | 10 | 6 |
p5 values, results of statistical testing within five groups of patients and are rather informative because of the small number of patients in each group; p3 values, result of statistical testing within three groups of patients. *P values significant at the 5% significance level. **P values significant at a significance level adjusted by Bonferroni correction (0.05/17 = 0.0029). For some parameters evaluated in tissue microarrays, information was not available in all patients. aA to C, three clusters; I to V, five clusters.